Introduction
In recent years, studies of the Akt/PKB family of protein kinases have revealed major roles in human pathology, including aging, diabetes, hypertrophy, and malignancy. These breakdowns in homeostatic physiology are due to alterations in the basic functions of cells: mitogenesis, growth, metabolism, and apoptosis susceptibility. The pleiotropic effects of Akt may be direct or indirect: Akt may coordinate multiple arms of signal transduction, each of which independently regulates a single facet of cell function such as cell growth, or Akt may regulate a core apparatus within the cell, which serves as a node to potentiate secondary effects on diverse cell functions. Here we describe the relationship between Akt signal transduction and cellular metabolism, and consider whether alterations in metabolism may be required for Akt effects on mitogenesis, growth, and survival.
Building a pathway that regulates cellular metabolism
It is well accepted that the metabolic program of insulinresponsive cells of the liver, skeletal muscle, and adipose tissues is not directly responsive to extrinsic nutrient conditions; instead, a signal transduction cascade must be activated to alter cellular metabolism. This principle is illustrated in the development of hyperglycemia associated with Type I diabetes, in which circulating glucose increases to harmful concentrations because there are not sufficient quantities of insulin to induce glucose uptake and storage (Saltiel and Kahn, 2001) . Insulin replacement therapy restores glucose homeostasis by inducing a signal transduction cascade that instructs cells to cease hepatic glucose production and increase glucose uptake and storage within muscle, adipose, and liver tissues. The Akt signal transduction pathway is responsible for passing insulin receptor instructions from the plasma membrane to the metabolic, transcription, and translation machinery within the cell (Burgering and Coffer, 1995; Brazil et al., 2004) . However, the Akt pathway is not exclusive to insulin receptor signaling; Akt is activated downstream of multiple classes of growth factor receptors, from receptor tyrosine kinases to cytokine receptors and integrins. It is becoming increasingly clear that in most cell types, activation of the Akt pathway by cell surface receptors dictates changes in cellular metabolism, coordinated with alterations in cell growth, mitogenesis, and susceptibility to apoptosis.
Upstream elements in the Akt signaling pathway consist of growth factor receptors, adapter proteins such as the Insulin Receptor Substrates (IRS), Class I phosphatidylinositol 3-kinase (PI3K) isoforms, and Akt/PKB kinases themselves (Figure 1 ). Akt activation requires phosphatidylinositol triphosphate (PIP3) generated by PI3K and phosphorylation on separate sites by the upstream kinases phosphatidylinositol-dependent kinase-1 (PDK1) and the mTOR : rictor complex (TORc2) (Alessi et al., 1997; Sarbassov et al., 2005) . The PTEN tumor suppressor protein is an inositol phosphatase that opposes PI3K activity by dephosphorylating PIP3. The balance between PI3K and PTEN activities regulates activation of three isoforms of Akt/ PKB: Akt1/PKBa, Akt2/PKBb, and Akt3/PKBg.
The Akt2 isoform has been most clearly implicated in the regulation of organismal metabolism. Akt2-deficient animals are hyperinsulinemic and hyperglycemic in fasting conditions, possibly due to reduced insulininduced glucose uptake mediated by the GLUT4 glucose transporter in liver cells (Cho et al., 2001; Garofalo et al., 2003) . GLUT4-dependent glucose transport is reduced in Akt2-deficient cells because of a failure to stimulate GLUT4 translocation from intracellular vesicles to the plasma membrane. Neither endogenous nor overexpressed Akt1 protein can compensate for loss of Akt2, suggesting Akt2-specific functions that are not simply due to expression patterns of Akt isoforms (Bae et al., 2003) . Indeed, Akt2 but not other Akt isoforms is directly associated with GLUT4-containing protein complexes (Calera et al., 1998 ). An Akt2-specific substrate involved in the regulation of insulin-stimulated GLUT4 translocation has recently been identified, known as Synip. Synip phosphorylation triggers its dissociation from syntaxin4 and assembly of a protein complex that mediates redistribution of GLUT4 vesicles to the plasma membrane (Yamada et al., 2005) . Thus, Akt2 plays an essential role in GLUT4-dependent glucose uptake in response to insulin signaling.
The ability to stimulate increased glucose uptake and metabolism is not exclusive to insulin and the tissues that regulate circulating glucose levels. Increased glucose uptake and metabolism in response to ligands such as EGF, IL-3, and TGF-b has been long appreciated in diverse cell types such as fibroblasts, hematopoietic progenitors, and kidney epithelial cells (Barnes and Colowick, 1976; Whetton et al., 1984; Boerner et al., 1985; Rathmell et al., 2000) . Akt1 and Akt2 are both important for signaling induced by growth factor receptors, since mice deficient in both isoforms exhibit dramatic defects in more cell lineages than mice deficient in only Akt1 or Akt2 (Peng et al., 2003) . Activation of Akt in response to growth factors or oncogenes is sufficient to cause increased transcription and plasma membrane localization of the glucose transporter GLUT1, which is the principle glucose transporter expressed in most cell types Barnes et al., 2005) . Akt activation also increases the overall rate of glycolysis, possibly through effects on a key rate-limiting step: phosphorylation of newly acquired glucose by hexokinase isoforms (Gottlob et al., 2001; Plas et al., 2001) . Akt causes translocation of hexokinase I and II to the mitochondrial outer membrane, where high concentrations of ATP favor enzymatic phosphorylation of glucose (Majewski et al., 2004) . Akt likely has other effects on regulatory elements of glycolysis, since increased GLUT1 and hexokinase expression only partially activate glycolysis to the levels observed with constitutive expression of Akt (Rathmell et al., 2003) .
Direct effects of Akt activation on metabolism are predominantly cytosolic, but the impact of altered cytoplasmic metabolism is reflected in mitochondria. Increased hexokinase association with the mitochondrial outer membrane appears to protect metabolite transport during apoptotic stimuli, preventing a deleterious buildup of mitochondrial membrane potential (Majewski et al., 2004) . Similarly, increased glycolysis supplies necessary nutrients to prevent a decline in mitochondrial metabolism in cells stressed by growth factor withdrawal . Akt can phosphorylate and activate ATP citrate lyase, an enzyme associated with the mitochondrial outer membrane that converts citrate from the TCA cycle into cytosolic acetyl CoA, potentially contributing to energy storage and fatty acid synthesis (Berwick et al., 2002; Bauer et al., in press ). Thus, Akt-driven alterations in cytosolic metabolism are propagated into changes in mitochondrial function.
Direct effects of Akt on glycolysis and mitochondrial function can be considered as 'immediate-early' metabolic responses. However, Akt also signals long-term alterations in cellular metabolism that can have profound effects on homeostatic regulation of circulating glucose and overall organism longevity. These effects are mediated in part through the regulation of Forkhead Box subclass O (FOXO) transcription factors ( Figure 1 ). In mammals, three structurally related FOXO isoforms are differentially expressing in tissues: FOXO1, FOXO3a, FOXO4 (previously known as FKHR, FKHRL1, and AFX, respectively) (Kaestner et al., 2000; Burgering and Kops, 2002) . Phosphorylation of these FOXO family proteins by Akt triggers their exclusion from the nucleus, and binding of 14-3-3 proteins (Brunet et al., 1999) . Another isoform, FOXO6, is regulated via Akt phosphorylation sites, but this isoform is not exported from the nucleus van der Heide et al., 2005) . Mice deficient in FOXO1, FOXO3a, and FOXO4 demonstrate a developmental requirement for FOXO1 and partial redundancy among other isoforms in tissues where they are coexpressed (Hosaka et al., 2004) . Under conditions of long-term Akt activation, phosphorylated forms of FOXO1 and FOXO3a are degraded in the proteasome, perhaps due to ubiquitination by E3 ligases such as Skp2 Huang et al., 2005) . Proteasomal degradation results in long-term suppression of the FOXO transcriptional program.
FOXO transcription factors directly regulate expression of key elements controlling cellular metabolism through both stimulatory and repressive effects on promoter activity (Ramaswamy et al., 2002) . In Caenorhabditis elegans, the FOXO family transcription factor DAF-16 is induced under glucose-limiting conditions, reprogramming cell metabolism to increase the capacity for oxidative metabolism. DAF-16 target genes include enzymes that detoxify reactive oxygen species (ROS), such as catalase and superoxide dismutase-3 (sod-3), as well as genes that promote fat metabolism, such as acyl CoA synthase enzymes (Lee et al., 2003; McElwee et al., 2003; Murphy et al., 2003) . Parallel functions of FOXOs in mammalian cells include induced expression of manganese-superoxide dismutase (MnSOD) and insulin-like growth factor binding protein-1 (IGFBP1), increasing the ability of cells to detoxify ROS while inhibiting growth factor receptor signaling (Brunet et al., 1999; Kops et al., 2002; Nemoto and Finkel, 2002 ). An oxidative metabolic program goes hand-in-hand with other functions of FOXO transcription factors: induction of cell cycle arrest and/or apoptosis. Decreased rates of proliferation correlate with less demand for glycolytic metabolism, and proapoptotic molecules such as Bax may be more effective in cells that depend on mitochondrial function for energy production Vander Heiden et al., 2001) .
Beyond direct transcriptional regulation of target genes, FOXO family transcription factors regulate cellular metabolism through their ability to associate with other transcriptional regulatory proteins. FOXO associations with Peroxisome Proliferator-activated receptor-g (PPARg), PPARg coactivator-1a (PGC-1a), and SIRT1 have been observed in various cell types. PPARg is a member of the nuclear hormone receptor family that is targeted by glitazone drugs used in treating diabetes. Binding of PPARg to FOXO1 represses transcription from IGFBP1 and phosphoenolpyruvate carboxykinase (PEPCK) promoter elements (Dowell et al., 2003) . Conversely, FOXO binding to PGC-1a promotes transcription of PEPCK and glucose 6-phosphatase under conditions that favor hepatic gluconeogenesis (Puigserver et al., 2003) . Thus, the effects of FOXO in regulating cell metabolism are influenced not only by Akt-dependent phosphorylation, but also by the antagonistic effects of binding to PPARg or PGC-1a.
Transcription of FOXO target genes is not a binary event dependent solely on promoter binding. Instead, expression of subsets of FOXO target genes can be enhanced or suppressed through regulation of FOXO acetylation status. The p300/CBP protein acetylases and the SIRT1 deacetylase form a complex with FOXO transcription factors and modulate FOXO acetylation (Brunet et al., 2004; Daitoku et al., 2004; Motta et al., 2004) . Deacetylation of FOXO transcription factors by SIRT1 increases transcription of cell cycle arrest genes such as p27Kip1, but represses FOXO transcription of proapoptotic genes such as Bim (Brunet et al., 2004; Motta et al., 2004) . Based on studies of promoter elements, the metabolic effects of SIRT1 deacetylation of FOXOs are expected to be decreased expression of PEPCK and IGFBP1, but increased MnSOD (Daitoku et al., 2004; Motta et al., 2004; van der Horst et al., 2004; Yang et al., 2005) . However, a recent study using the SIRT1-activating compound resveratrol has found that SIRT1 deacetylation of FOXO1 promotes hepatic cell expression of IGFBP1 and glucose-6-phosphatase (Frescas et al., 2005) . Complexity in regulating the transcriptional subsets induced by FOXO proteins is further increased by the ability of SIRT1 to directly associate with PGCÀ1a (Nemoto et al., 2005; Rodgers et al., 2005) . The SIRT1 : PGC-1a complex may oppose the activity of the SIRT1 : FOXO complex, since increased transcription from glucose-6-phosphatase and PEPCK promoters is observed upon formation of the SIRT1 : PGC-1a complex. Interestingly, SIRT1 interaction with PGC-1a does not prevent interaction with FOXO3a, suggesting the possibility for assembly of a trimolecular complex of FOXOs, SIRT1, and PGCÀ1a (Nemoto et al., 2005) .
The complexity of FOXO post-translational modification and the diversity of FOXO-containing protein complexes suggest that there remains much to be learned about how FOXOs mediate transcriptional alterations in cellular metabolic programs in response to Akt signaling. Systems-level studies of FOXO-controlled transcription in both insulin-responsive cells and other cell types are required to understand how Akt phosphorylation of FOXOs alters the cellular metabolic program to support cell growth, mitogenesis, and survival.
Similar to FOXO transcription factors, Akt inhibits tuberous sclerosis 2 (TSC2) function through direct phosphorylation (Figure 1) (Dan et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002) . TSC2 is a GTPase-activating protein (GAP) that functions in association with the putative chaperone TSC1 to inactivate the small G protein Rheb (Garami et al., 2003; Inoki et al., 2003a; Saucedo et al., 2003; Zhang et al., 2003) . Akt phosphorylation of TSC2 represses GAP activity, allowing Rheb to accumulate in a GTP-bound state. Rheb-GTP activates the protein kinase activity of the mammalian target of rapamycin (mTOR) in complex with the raptor adapter protein (mTOR : raptor or TORc1) which in turn phosphorylates downstream regulators of cellular translation: 4EBP-1 and p70S6K1 (Figure 1) .
Inactivation of TSC2 by Akt can be countered using rapamycin and related inhibitors, which interrupt signal transduction downstream of TSC2 by inhibiting the mTOR : raptor complex. Rapamycin suppresses cellular glycolysis and a mutant of mTOR that is no longer regulated by TSC1/TSC2 is sufficient to sustain glycolysis in the absence of extrinsic growth factors (Hardwick et al., 1999; Peng et al., 2002; Edinger et al., 2003) . mTOR activation is most directly linked with effects on protein translation, while comparatively little is known of how TSC2 and mTOR regulate the expression of glycolytic genes (Hay and Sonenberg, 2004 ). One possible link described in Saccharomyces cerevisiae is the transcription factor gcr-1p, which regulates transcription of multiple elements of the glycolytic pathway in a rapamycin-sensitive manner (Hardwick et al., 1999) . Links between mTOR and glycolysis in mammalian cells may involve increased translation of glycolytic enzymes or their transcriptional regulators, such as myc (Kim et al., 2004; West et al., 1998) .
Beyond regulation of glucose metabolism, the TSC2/ mTOR signal transduction arm is intricately linked to the regulation of cellular amino acid uptake. Inactivation of TSC2 and the resulting induction of mTOR kinase activity stimulates cellular amino-acid uptake, which may be important to support increased protein translation and expansion in cell size, two major consequences of mTOR activation (Schmidt et al., 1998; Schmelzle and Hall, 2000) . In response to mTOR : raptor activation, the amino-acid transporter-associated 4F2 heavy chain redistributes from intracellular vesicles to the plasma membrane in a rapamycin-sensitive manner, suggesting that Akt regulates trafficking of vesicles that contain amino-acid transporters, in a manner analogous to regulation of glucose transporters (Edinger and Thompson, 2002) . However, glucose transporter localization appears to be regulated directly by Akt, while amino-acid transporters are controlled by mTOR : raptor (Fingar et al., 1993; Yamada et al., 2005) . Thus, cellular conditions that alter mTOR : raptor signaling without inactivating Akt (such as metabolic deprivation, see below) could influence amino-acid transporters independent of effects on glucose transporters. Three classes of amino-acid transporters have been described, and newly identified transporters are still being classified (Hyde et al., 2003; Mackenzie and Erickson, 2004) . Each class of aminoacid transporter may be differentially regulated by mTOR activation, providing the cell with an ability to fine tune transporter activity according to growth factor receptor signaling and intracellular demands.
In addition to regulation of glucose and amino-acid metabolism, other metabolic programs within the cell, such as fatty acid metabolism and mitochondrial TCA cycle function, are regulated by FOXO, TSC2/mTOR, and other signal transduction arms downstream of Akt. Careful measurement of cellular bioenergetics suggests that Akt signal transduction dictates an increase in total cellular metabolism to anticipate the demands of increased growth, mitogenesis, and apoptosis resistance in response to activation of growth factor receptors and oncogenes Elstrom et al., 2004) . The Akt pathway is not exclusively controlled by the insulin receptor. Instead Akt is activated downstream of diverse extrinsic stimuli, allowing cells of all types to support the anabolic processes demanded by growth factors: mitogenesis, growth and apoptosis resistance.
Turning the tables: metabolic cues regulate Akt signaling
Insulin and extrinsic growth factors have long been recognized for their ability to induce alterations in mitogenesis, metabolism, and protein translation. To prevent the accumulation of partially translated proteins on ribosomes, the initiation of mRNA translation must be tightly coupled to cellular sensors that determine whether a cell has sufficient supplies of amino acids and energy to complete protein synthesis. Studies focusing on how cells regulate translation initiation led to the realization that growth factor signals directing increased protein synthesis can be trumped by the signal transduction cascades that sense insufficient availability of key nutrients, such as amino acids, glucose, and oxygen.
Decreased availability of amino acids blocks insulininduced and mTOR-dependent phosphorylation of key regulators of protein translation: p70S6K and 4EBP-1 (Hara et al., 1998; Wang et al., 1998) . Readdition of amino acids restored phosphorylation of both p70S6K and 4EBP-1 in a rapamycin-sensitive manner, leading to the proposal that mTOR functions as a 'checkpoint' enzyme coordinating the control of translation with amino-acid availability, similar to related kinases such as ATM, ATR, and DNA-PK (Hara et al., 1998) . The importance of mTOR as a checkpoint enzyme integrating multiple metabolic cues was first illustrated in studies of mTOR kinase activity, which showed that mTOR signaling is dependent not only on the presence of amino acids, but also on the continued production of energy from glycolysis and mitochondrial electron transport (Dennis et al., 1999) . Additional studies further extended this observation to demonstrate that mTOR-dependent phosphorylation of substrates is suppressed by hypoxia, ROS, and osmotic stresses (Arsham et al., 2002; Patel et al., 2002) . Thus, metabolites in the form of amino acids, glycolytic products, and oxygen can interrupt Akt signaling through the downstream kinase mTOR.
The molecular workings of metabolite checkpoints in Akt-TSC2-mTOR signal transduction are beginning to be elucidated. Inhibition of mTOR by amino-acid insufficiency is likely mediated through disruption of Rheb activation of mTOR:raptor. In amino-acidstarved cells, TSC2 RNAi prevents loss of p70S6K phosphorylation, while overexpression of Rheb allows cells to maintain high phosphorylation of mTOR : raptor substrates (Gao et al., 2002; Tee et al., 2003) . Conflicting results have recently been obtained using TSC2-deficient cells instead of RNAi; here amino-acid withdrawal suppressed p70S6K phosphorylation, suggesting that TSC1/TSC2 is not required to sense a decline in amino-acid availability . Determination of whether TSC2 or Rheb is the ultimate sensor of amino-acid sufficiency will require further understanding of the amino-acid detector molecules, and how they transduce information about amino acid sufficiency to both TSC2 and Rheb.
Inhibition of glycolysis by glucose withdrawal or addition of 2-deoxyglucose, a glucose analogue that blocks glycolysis, also interrupts Akt signaling by blocking mTOR-dependent phosphorylation events (Dennis et al., 2001) . TSC2 is again implicated in mediating the suppressive effects of energy challenge on mTOR : raptor activity. Under glucose-limiting conditions, intracellular concentrations of AMP rise, triggering phosphorylation and activation of the AMPactivated protein kinase (AMPK) by its upstream regulator, LKB1 (Hawley et al., 2003; Hong et al., 2003; Woods et al., 2003) . AMPK phosphorylates several sites within TSC2, activating TSC2 GAP activity and inhibiting Rheb activation of mTOR (Inoki et al., 2003b; Corradetti et al., 2004) . It is interesting to note that Akt phosphorylation of TSC2 is inhibitory, while AMPK phosphorylation is activating, thus establishing an antagonistic relationship between these two kinases. Cells that lack the ability to activate TSC2 in glucoselimiting conditions initiate apoptosis (Inoki et al., 2003b) . Recently, glucose-limiting conditions were shown to activate AMPK phosphorylation of p53, suggesting that adaptive responses to energy crisis require coordinated actions of the TSC2 and p53 tumor suppressors .
Low oxygen (hypoxia) also prevents Akt activation of mTOR. Hypoxic conditions stimulate hypoxia inducible factor-dependent transcription of Scylla/Charybdis in Drosophila and REDD1/RTP801 in mammalian cells (Shoshani et al., 2002; Brugarolas et al., 2004; Reiling and Hafen, 2004; Sofer et al., 2005) . Genetic approaches demonstrated that REDD1 acts downstream of Akt but requires TSC2 to repress TOR-dependent phenotypes such as increased cell growth. Interestingly, expression of Charybdis was necessary for developing flies to survive nutrient starvation, suggesting that REDD1 may also respond to energy-deprivation in addition to hypoxic responses . Indeed, REDD1 was recently shown to be required for dephosphorylation of p70S6K and 4EBP-1 in cells exposed to glucose-limiting conditions (Sofer et al., 2005) . Since AMPK phosphorylation of TSC2 is directly linked to the low glucose response, it is surprising to find REDD1 controlling TSC2 under these conditions as well. Even more surprising is the finding that in REDD1-null cells, TSC2 can no longer mediate decreased phosphorylation of p70S6K, even though TSC2 phosphorylation itself was intact (Sofer et al., 2005) . These studies may link hypoxia and glucose limitation into a common pathway that regulates mTOR activity. However, important questions remain to be answered before the role of REDD1 in regulating Akt-TSC2-mTOR signal transduction can be understood, such as defining the transcriptional activation of REDD1 in glucose-limiting conditions, and learning the molecular details of how REDD1 functions in repressing mTOR phosphorylation of substrates.
The Akt-FOXO arm of signal transduction is also subject to regulation by metabolic parameters within the cell. As previously noted, SIRT1 deacetylation can determine whether FOXO promotes expression of genes that induce apoptosis or cell cycle arrest. Since SIRT1-related protein acetylases consume NAD þ in deacetylating target proteins, changes in the total amount of nicotinamide dinucleotides, or alterations in the ratio of NAD þ /NADH can influence SIRT1 activity and hence FOXO acetylation. What cellular conditions might alter NAD þ availability? Increases in glycolytic metabolism driven by Akt can drive NAD þ reduction to NADH, as can the ratio of lactate/pyruvate within the cell (DRP and CBT unpublished observations). Genetic alterations that drive cell transformation were recently shown to increase the overall concentration of NAD þ and NADH (Ramanathan et al., 2005) . Alterations in FOXO acetylation in response to metabolic conditions may help explain why growth factor-stimulated cells have increased sensitivity to growth factor withdrawal: high levels of growth factor could increase NADH, depleting the NAD þ needed for SIRT1 activity to favor cell cycle arrest (Vander Heiden et al., 2001; Brunet et al., 2004) .
It is clear that limitations in the availability of glucose, amino acids, and oxygen directly interrupt signal transduction downstream of mTOR, affecting the rate of translation and other cell functions controlled by mTOR. However, interruption of mTOR signal transduction has far-reaching consequences for the entire Akt signal transduction cascade, since inactivation of mTOR indirectly activates Akt kinase activity through inactivation of a p70S6K-dependent feedback loop (Figure 2 ) (Radimerski et al., 2002) . Under nutrient-replete conditions, p70S6K activation downstream of growth factor receptors activates a negative feedback loop, which dampens upstream signals that activate Akt through effects on IRS-1 (Harrington et al., 2004; Manning, 2004; Um et al., 2004) . However, when nutrients are limiting, mTOR activation is blocked and Akt is free of p70S6K-dependent inhibition, resulting in greater intensity and longer duration of Akt signaling. Considering the effects of the feedback pathway on FOXO transcription, it is apparent that receptor-or oncogenemediated activation of Akt could be enhanced by metabolic perturbations, triggering further phosphorylation of FOXO. The intimate relationship between nutrient control of mTOR : raptor and p70S6K-negative regulation creates a reinforcing feedback circuit: Akt signaling is dampened when cells have sufficient nutrients, and is enhanced when one or more of the required nutrients is lacking (Figure 2 ). Nutrientdependent feedback regulation may elicit oscillatory behavior in Akt signaling as nutrients are acquired by the cell, fine-tuning Akt activation according to the relationship between extrinsic nutrient availability and intrinsic metabolic status.
Metabolism as a modulator of mitogenesis, growth, and survival
Building on a basic pathway that senses the cellular nutritional status and directs alterations in the cellular metabolic program, the Akt pathway has acquired through evolution the ability to regulate mitogenesis, growth, and apoptosis in multicellular organisms. Akt signaling through FOXO and TSC2 pathways demonstrates that Akt continues to exert its evolutionarily conserved role in regulating intrinsic cellular metabolism, through increases in glucose metabolism and amino-acid pools in response to stimulation with growth factors. Failure to sustain glycolytic metabolism, acquire necessary amino acids, or maintain access to oxygen can profoundly alter growth factor receptor signal transduction by inactivating mTOR : raptor while stimulating Akt and its effectors. The potential of rapamycin as a chemotherapeutic agent for treatment of malignancy may depend on its ability to inhibit cell growth, mitogenesis, and survival by recapitulating the effects of nutrient limitation: inhibiting mTOR : raptor and stimulating Akt activity. Viewed from this perspective, it is evident that successful implementation of the Akt metabolic program is a prerequisite for modulation of cellular mitogenesis, growth, and survival.
